Immunohistochemical methods to detect p53 were developed in the early 1990s, and because p53 is the “guardian of the genome,” it has been applied as a convenient surrogate for TP53 mutation status to predict the survival outcomes in patients with cancer [19,20,21]. The gene discussed is TP53; the disease is cancer.